United States-based Therapeutics Solutions International Inc (OTC Markets: TSOI) is planning to use its clinical-stage cancer immunotherapy StemVacs for the treatment of COVID-19 patients, it was reported on Monday.
The firm had earlier filed data with the US FDA that indicated that treatment of cancer patients with the product resulted in improved activity of a type of immunological cell named 'natural killer' cells.
'natural killer' cells have been seen to to inhibit SARS-CoV-2 and firms such as Celularity have received approval from the FDA to use pre-made 'natural killer' cells for the treatment of COVID-19 as part of clinical trials.
ELIAS Animal Health names new chief revenue officer
enGene Holdings names new senior vice president, Urologic Oncology and Clinical Development
HealthTrackRx names new chief medical officer
PureTech announces launch of Seaport Therapeutics with USD100m Series A financing
Orsini Specialty Pharmacy names new CFO and EVP of Trade Relations and Account Management
Enable Biosciences names new chief financial officer
Cadenza Bio names new director
Ligand Pharmaceuticals launches Pelthos Therapeutics to drive ZELSUVMI commercialisation